Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression.

Fiebiger WC, Scheithauer W, Traub T, Kurtaran A, Gedlicka C, Kornek GV, Virgolini I, Raderer M

Scandinavian journal of gastroenterology1 Feb 2002Cited by 12 (Europe PMC)

PMID11843061DOI10.1080/003655202753416911PepBankPUB-11843061

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialSafety outcome
In advanced biliary cancer, two patients reported mild nausea during lanreotide therapy.
In plain wordsIn advanced biliary cancer, two patients reported mild nausea during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableNausea
Study
n = 20
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Patients with mild nausea
2 patients
20 patients with advanced biliary cancer
Source sentences
Summary
Side effects were generally mild, only two patients complained of mild nausea and one patient had meteorism attributed to therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306101
02HumanNon-randomized trialSafety outcome
In advanced biliary cancer, one patient had meteorism attributed to lanreotide therapy.
In plain wordsIn advanced biliary cancer, one patient had gas buildup attributed to lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableMeteorism
Study
n = 20
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Patients with meteorism attributed to therapy
1 patients
20 patients with advanced biliary cancer
Source sentences
Summary
Side effects were generally mild, only two patients complained of mild nausea and one patient had meteorism attributed to therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306102
03HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, one lanreotide-treated patient had complete remission lasting 18 months before recurrence.
In plain wordsIn advanced biliary cancer, one lanreotide-treated patient had complete remission for 18 months before recurrence.
Peptide
Lanreotide
Outcome
Not applicableComplete remission
Study
n = 20
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Patients with complete remission
1 patients
20 patients with advanced biliary cancer
Duration of complete remission
18 months
one patient before recurrence
Source sentences
Summary
Therapeutic results, however, were disappointing, with only one patient demonstrating complete remission (CR), which lasted for 18 months before diagnosis of recurrence.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306103
04HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, four lanreotide-treated patients had stable disease lasting 3.5 to 9+ months.
In plain wordsIn advanced biliary cancer, four lanreotide-treated patients had stable disease for 3.5 to 9+ months.
Peptide
Lanreotide
Outcome
Not applicableStable disease
Study
n = 20
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Patients with stable disease
4 patients
20 patients with advanced biliary cancer
Duration of stable disease
3.5 to 9 months
patients with stable disease; upper bound reported as 9+
Source sentences
Summary
Four patients had stable disease (SD) lasting between 3.5 and 9+ months accompanied by weight gain and improvement in performance status in 2 cases, while the remaining 15 patients progressed during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306104
05HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, 15 patients progressed during lanreotide therapy.
In plain wordsIn advanced biliary cancer, 15 patients had disease progression during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicableDisease progression
Study
n = 20
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Patients who progressed during therapy
15 patients
20 patients with advanced biliary cancer
Source sentences
Summary
Four patients had stable disease (SD) lasting between 3.5 and 9+ months accompanied by weight gain and improvement in performance status in 2 cases, while the remaining 15 patients progressed during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306107
06HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, median time to progression during lanreotide therapy was 2.5 months (range 1-18).
In plain wordsIn advanced biliary cancer, median time to progression during lanreotide treatment was 2.5 months.
Peptide
Lanreotide
Outcome
Not applicableTime to progression
Study
n = 20
Outcome group
Tumor growth · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Median time to progression
2.5 months
20 patients with advanced biliary cancer
Time to progression range
1 to 18 months
20 patients with advanced biliary cancer
Source sentences
Summary
The median time to progression was 2.5 months (range 1-18), and the median survival was 4.5 months (range 1.5-18+ months).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306108
07HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, median survival with lanreotide was 4.5 months (range 1.5-18+ months).
In plain wordsIn advanced biliary cancer, median survival with lanreotide was 4.5 months.
Peptide
Lanreotide
Outcome
Not applicableSurvival
Study
n = 20
Outcome group
Mortality · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Median survival
4.5 months
20 patients with advanced biliary cancer
Survival range
1.5 to 18 months
20 patients with advanced biliary cancer; upper bound reported as 18+
Source sentences
Summary
The median time to progression was 2.5 months (range 1-18), and the median survival was 4.5 months (range 1.5-18+ months).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306109
08HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, two patients with stable disease gained weight during lanreotide therapy.
In plain wordsIn advanced biliary cancer, two patients with stable disease gained weight during lanreotide treatment.
Peptide
Lanreotide
Outcome
IncreaseWeight gain
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Stable-disease cases with weight gain
2 cases
patients with stable disease; source says 2 cases
Source sentences
Summary
Four patients had stable disease (SD) lasting between 3.5 and 9+ months accompanied by weight gain and improvement in performance status in 2 cases, while the remaining 15 patients progressed during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306105
09HumanNon-randomized trialEfficacy outcome
In advanced biliary cancer, two patients with stable disease improved performance status during lanreotide therapy.
In plain wordsIn advanced biliary cancer, two patients with stable disease improved physical function during lanreotide treatment.
Peptide
Lanreotide
Outcome
IncreasePerformance status
Study
n: not reported in source
Outcome group
Exercise and physical function · Cancer
Studied dose
30 mg every 2 weeks · deep intramuscular · until progression or withdrawalAs given in this study (human).
Measurements
Stable-disease cases with improved performance status
2 cases
patients with stable disease; source says 2 cases
Source sentences
Summary
Four patients had stable disease (SD) lasting between 3.5 and 9+ months accompanied by weight gain and improvement in performance status in 2 cases, while the remaining 15 patients progressed during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty consecutive patients with histologically verified primary hepatic cholangiocellular cancer or primary adenocarcinoma of the gallbladder were enrolled in the study.
Summary · context
Thirty milligrams of a slow-release formulation of LAN was administered by deep intramuscular injection every 2 weeks until progression or patients wished to withdraw.
Report a problemFND-1184306106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.